Finance

Roʻyxatlar
Nega MRK oshdi 3,74%?
Batafsil oʻrganish
MRK:NYSE
Merck & Co Inc
147,29 US$
+3,74%
(+5,31) 1K
14-okt, 12:23:55 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
MRK tikeri uchun statistika yaratilmoqda...
Ochish
143,10 US$
Yuqori
147,68 US$
Past
142,66 US$
Bozor kapitali
363,39 mlrd
Oʻrtacha hajm
9,33 mln
Hajmi
2,64 mln
Dividend
2,31%
Choraklik dividendlar
0,85 US$
Eks-dividend sanasi
15-sen, 2026
P/E koeffitsiyenti
117,64
52 haftalik eng yuqori
156,92 US$
52 haftalik eng past
82,01 US$
Aksiya boʻyicha daromad
1,25 US$
Beta
0,21
Muomaladagi aksiyalar
2,47 mlrd
Xodimlar soni
74 ming
Ochish
143,10 US$
Yuqori
147,68 US$
Past
142,66 US$
Bozor kapitali
363,39 mlrd
Oʻrtacha hajm
9,33 mln
Hajmi
2,64 mln
Dividend
2,31%
Choraklik dividendlar
0,85 US$
Eks-dividend sanasi
15-sen, 2026
P/E koeffitsiyenti
117,64
52 haftalik eng yuqori
156,92 US$
52 haftalik eng past
82,01 US$
Aksiya boʻyicha daromad
1,25 US$
Beta
0,21
Muomaladagi aksiyalar
2,47 mlrd
Xodimlar soni
74 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
Merck & Co Inc haqida
CEORobert M Davis
Xodimlar soni74 ming
Asos solingan1-yan, 1891
Bosh ofislar-
Sektor-
Veb-saytmerck.com
Analitik reytinglar
Oxirgi 3 oyda MRK aksiyalari boʻyicha reyting bergan 21 tahlilchi xulosasiga koʻra
Sotib olish
Sotib olish
15
Ushlab qolish
6
Sotish
0
12 oylik prognoz
Oxirgi 3 oyda MRK uchun 12 oylik narx maqsadlarini taklif qilgan 21 Wall Street tahlilchisi xulosasiga koʻra
Eng yuqori
Joriy 147,29 US$
180,00 US$ (+22,21%)
O‘rtacha
160,24 US$ (+8,79%)
Eng past
105,00 US$ (-28,71%)
Analitik
Tavsiya
Amal
Kutilayotgan narx
Prognoz
Sana
Evan Seigerman
BMO Capital
Buy
Maintained
170,00 US$
+15,4%
10/12/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
145,00 US$
-1,6%
10/11/2026
Daina Graybosch
Leerink Partners
Buy
Maintained
161,00 US$
+9,3%
10/12/2026
Trung Huynh
RBC Capital
Hold
Reiterated
145,00 US$
-1,6%
10/12/2026
Geoff Meacham
Citi
Hold
Maintained
145,00 US$
-1,6%
10/13/2026
Emily Field
Barclays
Buy
Maintained
150,00 US$
+1,8%
10/12/2026
Michael Yee
UBS
Buy
Maintained
175,00 US$
+18,8%
10/09/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
163,00 US$
+10,7%
10/09/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
177,00 US$
+20,2%
10/07/2026
Chris Schott
J.P. Morgan
Buy
Maintained
165,00 US$
+12%
10/05/2026
Asad Haider
Goldman Sachs
Buy
Maintained
160,00 US$
+8,6%
09/30/2026
Louise Chen
Scotiabank
Buy
Maintained
180,00 US$
+22,2%
09/29/2026
Steve Scala
TD Cowen
Hold
Maintained
155,00 US$
+5,2%
09/22/2026
Nico Chen
DBS
Buy
Maintained
180,00 US$
+22,2%
09/11/2026
Rajesh Kumar
HSBC
Buy
Maintained
172,00 US$
+16,8%
09/10/2026
Vamil Divan
Guggenheim
Buy
Reiterated
170,00 US$
+15,4%
09/08/2026
Courtney Breen
Bernstein
Hold
Maintained
105,00 US$
-28,7%
09/07/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
170,00 US$
+15,4%
09/04/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
170,00 US$
+15,4%
08/24/2026
Alexandria Hammond
Wolfe Research
Buy
Maintained
180,00 US$
+22,2%
08/25/2026
Luisa Hector
Berenberg Bank
Hold
Maintained
127,00 US$
-13,8%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
138,00 US$
-6,3%
05/19/2026
Unknown Analyst
Argus Research
Buy
Reiterated
130,00 US$
-11,7%
05/08/2026
Hans Engel
Erste Group
Hold
Maintained
-
-
05/05/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Maintained
179,00 US$
+21,5%
04/17/2026
James Shin
Deutsche Bank
Buy
Upgraded
150,00 US$
+1,8%
02/13/2026
Oxirgi hisobot
4-avg, 2026
Moliya davri
Ch.2 2026
-0,13 US$ / -0,26 US$
+49,43%musbat
Taxminiy daromad (USD)
16,61 mlrd / 16,37 mlrd
+1,46%musbat
Q2 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
17,28 mlrd
16,40 mlrd
16,29 mlrd
16,61 mlrd
Sotilgan mahsulotning tannarxi
3,74 mlrd
4,30 mlrd
3,88 mlrd
4,13 mlrd
Daromad narxi
3,74 mlrd
4,30 mlrd
3,88 mlrd
4,13 mlrd
Tadqiqot va ishlanmalarga xarajatlar
4,00 mlrd
4,00 mlrd
3,56 mlrd
9,74 mlrd
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
2,48 mlrd
2,73 mlrd
2,57 mlrd
2,78 mlrd
Operatsion xarajatlar
6,48 mlrd
6,73 mlrd
6,12 mlrd
12,52 mlrd
Jami operatsion xarajatlar
10,23 mlrd
11,02 mlrd
10,00 mlrd
16,65 mlrd
Operatsion daromad
7,05 mlrd
5,38 mlrd
6,29 mlrd
-40,00 mln
Boshqa nooperatsion daromad
-
41,00 mln
42,00 mln
59,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
6,74 mlrd
3,42 mlrd
-3,53 mlrd
-683,00 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
6,76 mlrd
4,98 mlrd
5,85 mlrd
-508,00 mln
Daromad soligʻi boʻyicha xarajat
958,00 mln
458,00 mln
709,00 mln
654,00 mln
Amaldagi soliq stavkasi
14,20%
13,39%
-20,06%
-95,75%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
5,78 mlrd
2,96 mlrd
-4,24 mlrd
-1,34 mlrd
Sof foyda marjasi
33,49%
18,07%
-26,03%
-8,04%
Har bir aksiya foydasi
2,58
2,04
-1,28
-0,13
Foizlar va investitsiyalardan olingan daromadlar
96,00 mln
69,00 mln
35,00 mln
35,00 mln
Foizlarni toʻlash xarajatlari
-327,00 mln
-411,00 mln
-479,00 mln
-525,00 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-231,00 mln
-342,00 mln
-444,00 mln
-490,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
8,15 mlrd
6,79 mlrd
7,69 mlrd
1,43 mlrd
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
Insayder tranzaksiyalari
Insayder tranzaksiyalari maʼlumotlari tashqi manbalardan olingan. Batafsil
Insayder
Joylashuvi
Turi
Sana
Aksiyalar
Miqdor
1-sahifa
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari